title: Restoration of central nervous system alpha-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type 2 vector delivery.
abstract: BACKGROUND
  Finding efficient central nervous system (CNS) delivery approaches has been the major challenge facing therapeutic development for treating diseases with global neurological manifestation, such as mucopolysaccharidosis (MPS) IIIB, a lysosomal storage disease, caused by autosomal recessive defect of alpha-N-acetylglucosaminidase (NaGlu). Previously, we developed an approach, intracisternal (i.c.) injection, to deliver recombinant adeno-associated viral (rAAV) vector to the CNS of mice, leading to a widespread periventricular distribution of transduction.
  
  
  METHODS
  In the present study, we delivered rAAV2 vector expressing human NaGlu into the CNS of MPS IIIB mice by an i.c. injection approach, to test its therapeutic efficacy and feasibility for treating the neurological manifestation of the disease.
  
  
  RESULTS
  We demonstrated significant functional neurological benefits of a single i.c. vector infusion in adult MPS IIIB mice. The treatment slowed the disease progression by mediating widespread recombinant NaGlu expression in the CNS, resulting in the reduction of brain lysosomal storage pathology, significantly improved cognitive function and prolonged survival. However, persisting motor function deficits suggested that pathology in areas outside the CNS contributes to the MPS IIIB behavioral phenotype. The therapeutic benefit of i.c. rAAV2 delivery was dose-dependent and could be attribute solely to the CNS transduction because the procedure did not lead to detectable transduction in somatic tissues.
  
  
  CONCLUSIONS
  A single IC rAAV2 gene delivery is functionally beneficial for treating the CNS disease of MPS IIIB in mice. It is immediately clinically translatable, with the potential of improving the quality of life for patients with MPS IIIB.
authors.affiliation: Center for Gene Therapy, Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA.
authors.forename: Haiyan
authors.initials: H
authors.lastname: Fu
authors.forename: Julianne
authors.initials: J
authors.lastname: DiRosario
authors.forename: Lu
authors.initials: L
authors.lastname: Kang
authors.forename: Joseph
authors.initials: J
authors.lastname: Muenzer
authors.forename: Douglas M
authors.initials: DM
authors.lastname: McCarty
mesh_terms: D000118:Acetylglucosaminidase / Q000378:metabolism*; D000818:Animals; D001522:Behavior, Animal; D001921:Brain / Q000201:enzymology* / Q000473:pathology; D002552:Cerebral Ventricles / Q000378:metabolism; D003071:Cognition; D000229:Dependovirus / Q000235:genetics*; D018450:Disease Progression; D018014:Gene Transfer Techniques; D005822:Genetic Vectors / Q000235:genetics* / Q000493:pharmacokinetics; D016679:Genome, Viral / Q000235:genetics; D008247:Lysosomes / Q000378:metabolism; D051379:Mice; D009084:Mucopolysaccharidosis III / Q000201:enzymology / Q000473:pathology / Q000628:therapy*; D011994:Recombinant Proteins / Q000378:metabolism; D011995:Recombination, Genetic; D016019:Survival Analysis
chemical_list: D011994:Recombinant Proteins; C033079:alpha-N-acetyl-D-glucosaminidase; D000118:Acetylglucosaminidase